About Beam Therapeutics
Our vision is to provide life-long cures for patients suffering from serious diseases.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, Massachusetts
- Founded
- 2017
- Company type
- Public Company
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes.
Our dream is to provide life-long cures for patients suffering from serious diseases.
The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
Specialties
- gene therapy
- base editing
- gene editing
- precision medicines
- CRISPR
- CRISPR Cas9
- genetic diseases
- rare diseases
- hematology
- lipid nanoparticles
- LNP
- vector production
- AAV
- In vivo
- ex vivo
- Liver
- mRNA Production
- mRNA
- DNA
- RNA
- Cas9
- drug development
- drug delivery
- immunology
- formulation development
- virology
- viral delivery
- nanoparticles formulation
- structural biology
- cell biology
- protein sciences
- and cell therapy
Company locations
238 Main St, Cambridge, Massachusetts 02142, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 80,766
- People linked to this company
- 573
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.